Lumis International
Lumis International is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
Investigator initiated clinical trial of dantrolene as a treatment for Darier disease
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available6 trial-level findings · Read insights
- The single-center Swedish trial enrolled 16 participants versus the planned sample size of 20; 10 contributed paired data to the primary analysis.
- Recruitment used the Karolinska University Hospital dermatology clinic, national Swedish dermatology networks, Swedish online patient communities, and relatives of enrolled participants.
- Three of 19 screened participants failed screening because of a PGA score below 3 or incompatible concomitant medication.
- Thirteen of 16 enrolled participants required a three-month systemic-therapy washout, during which mean PGA increased from 3.0 to 3.3 and mean DLQI from 9.9 to 12.8.
- Six of 16 participants discontinued before 6 months because of insufficient clinical response, and no post-discontinuation assessments were collected per protocol.
- At 9-month follow-up, 6 of 10 assessed participants had restarted an oral retinoid, so the further reduction in PGA could not be attributed to a persistent dantrolene effect.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Lumis International?
The 2026-10-09 snapshot links Lumis International to 1 distinct CTIS trials. Recorded services include Regulatory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Lumis International?
The most frequently recorded therapeutic areas are Dermatology, Genetic and Congenital Disorders. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Lumis International conducted?
The linked trials record locations in 1 country, including Sweden. These are trial locations, not confirmed office locations or countries where Lumis International delivered services.
What can this page tell me about Lumis International's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Lumis International. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Lumis International GmbH